PGF and medulloblastoma: The promising preclinical findings of anti-PlGF in HCC but also in other tumour types such as medulloblastoma [35], together with the acceptable safety profile of anti-PlGF administration in Phase I clinical trials, have attracted attention to PlGF as a potential target for therapy.